HomeCompareHOYFF vs JNJ

HOYFF vs JNJ: Dividend Comparison 2026

HOYFF yields 3.67% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HOYFF wins by $15.3K in total portfolio value
10 years
HOYFF
HOYFF
● Live price
3.67%
Share price
$34.69
Annual div
$1.27
5Y div CAGR
23.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.6K
Annual income
$6,120.16
Full HOYFF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HOYFF vs JNJ

📍 HOYFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHOYFFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HOYFF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HOYFF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HOYFF
Annual income on $10K today (after 15% tax)
$311.77/yr
After 10yr DRIP, annual income (after tax)
$5,202.14/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, HOYFF beats the other by $1,216.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HOYFF + JNJ for your $10,000?

HOYFF: 50%JNJ: 50%
100% JNJ50/50100% HOYFF
Portfolio after 10yr
$37.9K
Annual income
$5,404.78/yr
Blended yield
14.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HOYFF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
2.5
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HOYFF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHOYFFJNJ
Forward yield3.67%2.13%
Annual dividend / share$1.27$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.6%28%
Portfolio after 10y$45.6K$30.3K
Annual income after 10y$6,120.16$4,689.40
Total dividends collected$21.8K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: HOYFF vs JNJ ($10,000, DRIP)

YearHOYFF PortfolioHOYFF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,153$453.35$10,592$272.30+$561.00HOYFF
2$12,518$584.08$11,289$357.73+$1.2KHOYFF
3$14,152$757.26$12,123$472.89+$2.0KHOYFF
4$16,131$988.89$13,141$629.86+$3.0KHOYFF
5$18,562$1,302.09$14,408$846.81+$4.2KHOYFF
6$21,593$1,730.79$16,021$1,151.60+$5.6KHOYFF
7$25,430$2,325.67$18,122$1,588.22+$7.3KHOYFF
8$30,374$3,163.88$20,930$2,228.20+$9.4KHOYFF
9$36,865$4,365.26$24,792$3,191.91+$12.1KHOYFF
10$45,566$6,120.16$30,274$4,689.40+$15.3KHOYFF

HOYFF vs JNJ: Complete Analysis 2026

HOYFFStock

Huhtamäki Oyj manufactures and sells packaging products in the United States, Germany, India, the United Kingdom, Australia, Thailand, China, South Africa, Russia, the United Arab Emirates, Findland, and internationally. It operates in foodservice packaging, flexible packaging, and fiber packaging business areas. The company offers single and double-wall paper cups, coffee cups, cold drinks cups, cup carriers, lids, accessories, and short run prints of customized paper cups; take away trays, containers, clamshells, scoops, bowls, wraps, and various accessories for take-away and dining; and egg trays, egg cartons, fruit trays, and wine bottle separators. It also provides multilayer films, wrappers, labels, pouches, and various reclose and print options for coffee, tea, juice, energy drink, and alcoholic beverage packaging; and stand up pouches, food pouches, multilayer packaging, and foils for ice cream, soups, biscuits, confectionary, dry foods, and other retail foods. In addition, the company offers ready-to-eat pet food packaging, such as retort pouches and barrier laminates, as well as open and reclosable bags, and pouches in aluminum foil and non-foil transparent structures; packaging and labels for personal and home care products; tube laminates for toothpaste and other tubes; and blister packaging materials and pharmaceutical packaging. Further, it provides catering disposables and vending cups; food service paper and disposable tableware to foodservice operators, fast food restaurants, and coffee shops; packaging solutions for retail business; flexible packaging solutions. Huhtamäki Oyj was founded in 1920 and is headquartered in Espoo, Finland.

Full HOYFF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HOYFF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HOYFF vs SCHDHOYFF vs JEPIHOYFF vs OHOYFF vs KOHOYFF vs MAINHOYFF vs ABBVHOYFF vs MRKHOYFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.